<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute myeloid leukemia: Induction therapy in medically fit adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute myeloid leukemia: Induction therapy in medically fit adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute myeloid leukemia: Induction therapy in medically fit adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geoffrey Uy, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bob Lowenberg, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laura C Michaelis, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute myeloid leukemia (AML) describes a heterogeneous group of aggressive blood cancers that arise from malignant transformation and clonal expansion of hematopoietic precursor cells in the bone marrow. AML interferes with production of normal blood cells, which can cause fatigue, weakness, infection, bleeding, and other potentially life-threatening complications. Up to 40 percent of patients with de novo AML can achieve long-term remission/cure, but this generally requires intensive remission induction therapy that is suitable only for patients with adequate medical fitness. Because of age-related comorbidities, caution should be used when considering intensive chemotherapy for patients who are ≥75 years.</p><p>This topic discusses remission induction therapy for medically fit adults with de novo AML.</p><p>Other topics related to initial management of AML are provided separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/94786.html" rel="external">"Acute myeloid leukemia in adults: Overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4530.html" rel="external">"Acute myeloid leukemia: Management of medically unfit adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/122864.html" rel="external">"Therapy-related myeloid neoplasms: Management and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H2819672883"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Induction therapy for AML in medically fit patients involves intensive treatment with a significant risk of complications from the underlying disease and its treatment. Treatment should be administered in a center with the expertise and resources to manage AML.</p><p>The following features of induction therapy must be considered in managing a patient with AML:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of therapy</strong> – The goal of therapy for AML in medically fit patients is to achieve long-term survival and possible cure while limiting short-term and long-term adverse effects of treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Treatment of AML is guided by medical fitness, clinical presentation, cytogenetics, and molecular features of the leukemic blasts:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fitness</strong> – Medical fitness is judged by performance status and comorbid conditions. There is no specific age threshold, but many centers limit intensive induction therapy for AML to patients either ≤70 or ≤75 years with adequate organ function. (See <a class="local">'Medical fitness'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Classification and risk stratification</strong> – The AML subtype should be identified, and the risk category determined, as these features will affect induction therapy and postremission treatment, as well as outcomes. (See <a class="local">'Classification and risk stratification'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Timing</strong> – Induction therapy should begin promptly, but it is more important to perform an adequate diagnostic work-up, stabilize the patient's condition, and control disease complications/emergencies than it is to start chemotherapy immediately [<a href="#rid1">1,2</a>]. However, for patients who are medically unstable due to complications or emergencies associated with the leukemia, prompt initiation of induction therapy may be the most efficient means of medical stabilization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The mainstay of induction therapy for medically fit adults with AML is intensive treatment with <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> plus an anthracycline. Induction therapy differs for patients with or without <em>FLT3</em> mutation. (See <a class="local">'Initial therapy'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other acceptable regimens for AML induction therapy are discussed below. (See <a class="local">'Alternative induction regimens'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who are unlikely to tolerate such intensive treatment, treatments that can alleviate symptoms, improve the quality of life, and prolong survival are discussed separately. (See  <a class="medical medical_review" href="/d/html/4530.html" rel="external">"Acute myeloid leukemia: Management of medically unfit adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Management of special scenarios, including limited cardiac function, pregnancy, and others are discussed below. (See <a class="local">'Special scenarios'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive care</strong> – Clinical assessment, symptom management, and administration of blood products and antimicrobial agents to manage the prolonged cytopenias and infections associated with induction therapy are discussed below. (See <a class="local">'Adjunctive care'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response to induction therapy</strong> – Evaluation of the response to therapy is needed to choose postremission management or treat refractory disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The initial response to therapy is evaluated at the hematologic nadir. (See <a class="local">'Nadir response assessment'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Findings from the nadir assessment determine if a reinduction course will be administered. (See <a class="local">'Reinduction (second attempt)'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Remission status is determined after hematologic recovery and is judged by bone marrow findings; clinical and hematologic parameters; and assessment of measurable residual disease. (See <a class="local">'Remission status'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical emergencies</strong> – Hyperleukocytosis/leukostasis; tumor lysis syndrome; bleeding and coagulation disorders; and neurologic complications are discussed below. (See <a class="local">'Emergencies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postremission management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monitoring for relapse and complications of therapy is discussed below. (See <a class="local">'Monitoring'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Consolidation and/or maintenance therapy are important aspects of long-term control/cure of AML and are discussed separately. (See  <a class="medical medical_review" href="/d/html/4533.html" rel="external">"Acute myeloid leukemia in younger adults: Post-remission therapy"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PRETREATMENT</span><span class="headingEndMark"> — </span>The patient is evaluated for AML-related complications and emergencies and assessed for comorbidities that may affect the ability to tolerate intensive therapy.</p><p class="headingAnchor" id="H3"><span class="h2">Clinical evaluation</span><span class="headingEndMark"> — </span>The history and physical examination should evaluate comorbid illnesses (eg, heart disease, liver or kidney dysfunction, uncontrolled diabetes mellitus) and other conditions (eg, prior hematologic and oncologic disorders or cytotoxic therapy) that might affect management.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Organ function</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Heart disease</strong> – Special attention to cardiac function is required because of the large volumes of intravenous (IV) fluids administered during remission induction therapy and the routine use of anthracyclines.</p><p></p><p class="bulletIndent2">Management for patients with congestive failure or dysrhythmias that might preclude anthracycline use is discussed below. (See <a class="local">'Limited cardiac function'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Liver disease</strong> – Liver disease may affect the dose and schedule of anthracycline administration.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Kidney disease</strong> – Renal insufficiency might affect the schedule and dose of <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> and influence management of tumor lysis syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug allergies</strong> – History of allergies to antibiotics and other drugs should be noted since virtually every patient will require antibiotic therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections</strong> – History of active infections or latent infections that can reactivate or worsen in the setting of immunosuppression should be reviewed, including hepatitis B virus, hepatitis C virus, herpes simplex virus, cytomegalovirus, human immunodeficiency virus (HIV), and tuberculosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alloimmunization</strong> – Alloantibodies arising from prior transfusions or multiple pregnancies may presage transfusion reactions or other complications of red blood cell or platelet transfusions. (See  <a class="medical medical_review" href="/d/html/7922.html" rel="external">"Refractoriness to platelet transfusion", section on 'Factors associated with platelet refractoriness'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prior hematologic or malignant disorders</strong> – Distinctive management may be required for patients with a preexistent hematologic condition, prior cytotoxic therapy, or a familial/germline disorder that predisposes to AML.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Secondary leukemia</strong> – Secondary AML refers to AML that arises from a prior hematologic condition (eg, myelodysplastic syndromes/neoplasms, myeloproliferative neoplasms). Management is discussed below. (See <a class="local">'Secondary and therapy-related AML'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Therapy-related myeloid neoplasms</strong> – Patients with AML who previously received cytotoxic agents or radiation therapy are considered to have therapy-related myeloid neoplasms. Such patients may require special management, especially if there is chronic organ injury from their primary disorder or unfavorable disease biology (eg, <em>TP53</em> mutation) associated with prior treatment. (See  <a class="medical medical_review" href="/d/html/122864.html" rel="external">"Therapy-related myeloid neoplasms: Management and prognosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Germline or familial predisposition</strong> – AML in the setting of a familial/inherited disorder may require distinctive management.</p><p></p><p class="bulletIndent2">These conditions may be suspected if there is personal or family history of prior hematologic or other malignancies, unexplained cytopenias, certain somatic stigmata (eg, congenital limb anomalies, deafness, premature graying, skin or nail abnormalities, unexplained organ dysfunction), or genetic abnormalities involving<em> RUNX1</em>,<em> ETV6</em>, <em>GATA2</em>,<em> </em>or<em> DDX41</em>.</p><p></p><p class="bulletIndent2">Evaluation and diagnosis of germline disorders are discussed separately. (See  <a class="medical medical_review" href="/d/html/93183.html" rel="external">"Familial disorders of acute leukemia and myelodysplastic syndromes"</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>The following laboratory studies should be performed  (<a class="graphic graphic_table graphicRef112198" href="/d/graphic/112198.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematology</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count with white blood cell (WBC) differential count.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Review of blood smear (≥200 nucleated cells).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coagulation</strong> – Prothrombin time/international normalized ratio, activated partial thromboplastin time, fibrinogen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemistries</strong> – Electrolytes, glucose, renal function tests, calcium, phosphorus, uric acid, liver function tests, albumin, total protein, and lactate dehydrogenase.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infectious</strong> – Serologic testing for hepatitis A, B, and C; HIV; herpes simplex virus; cytomegalovirus; varicella zoster virus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human leukocyte antigen typing</strong> – Human leukocyte antigen (HLA) typing should be performed for patients who may be candidates for hematopoietic cell transplantation (HCT). HLA class I typing should be performed in case of refractoriness to platelet transfusion due to HLA alloantibodies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urine analysis</strong> – If clinically warranted.</p><p></p><p class="headingAnchor" id="H3537362401"><span class="h2">Other evaluation and management</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Electrocardiogram</strong> – Arrhythmias and baseline prolongation of the QTc interval should be noted.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ejection fraction</strong> – Echocardiogram or radionuclide ventriculography is performed to assess cardiac function. (See  <a class="medical medical_review" href="/d/html/5331.html" rel="external">"Tests to evaluate left ventricular systolic function"</a>.)</p><p></p><p class="bulletIndent1">Management of otherwise-fit patients with impaired cardiac function is discussed below. (See <a class="local">'Limited cardiac function'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic</strong> – Routine screening<strong> </strong>with a lumbar puncture (LP) is <strong>not</strong> indicated for patients who are asymptomatic at the time of diagnosis.</p><p></p><p class="bulletIndent1">Evaluation and management for patients with unexplained neurologic abnormalities at diagnosis are discussed separately. (See  <a class="medical medical_review" href="/d/html/4521.html" rel="external">"Involvement of the central nervous system (CNS) with acute myeloid leukemia (AML)"</a>.)</p><p></p><p class="bulletIndent1">Some experts suggest performing a diagnostic LP for patients with high-risk features for central nervous system (CNS) involvement (eg, WBC count &gt;100,000/microL or AML with monocytic features).</p><p></p><p class="bulletIndent1">The CNS should be reevaluated after achieving systemic remission. (See <a class="local">'Response evaluation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central venous catheter</strong> – A central venous access catheter, such as a percutaneous IV central catheter, with two or three independent lumens should be implanted. Use of fully implantable devices should be avoided during induction chemotherapy because of the higher risks of bleeding or infection and impediments to rapid removal in the event of an infection. (See  <a class="medical medical_review" href="/d/html/8194.html" rel="external">"Central venous access in adults: General principles"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dental evaluation</strong> – A professional dental evaluation may be warranted, especially for patients with poor dentition/dental health, to identify and address possible infectious foci.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest radiograph</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fertility</strong> – People with childbearing potential should receive counseling about the potential effect of treatment on fertility and options for fertility preservation. Individuals of childbearing potential should have a serum pregnancy test. (See  <a class="medical medical_review" href="/d/html/7440.html" rel="external">"Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"</a>.)</p><p></p><p class="headingAnchor" id="H2920124881"><span class="h2">Medical fitness</span><span class="headingEndMark"> — </span>Medical fitness is determined by the patient's performance status and the nature and severity of comorbid conditions. Fitness for intensive therapy is not determined by chronologic age per se.</p><p>There are no absolute criteria for classification of fitness, and the assessment should consider both preexistent conditions and the effects of the leukemia itself. We attempt to address medical comorbidities and/or improve the patient's clinical status before excluding an individual as a candidate for intensive treatment.</p><p>We do not apply an upper age limit for intensive treatment of AML, but caution is warranted for patients ≥75 years. Clinical trials have applied various criteria for inclusion, and the upper limit for inclusion has increased over time.</p><p>We use the following instruments to judge medical fitness:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Performance status</strong> – The following instruments and scores  (<a class="graphic graphic_table graphicRef57945" href="/d/graphic/57945.html" rel="external">table 2</a>) are generally acceptable for assessing fitness for intensive induction therapy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Eastern Cooperative Oncology Group performance status (ECOG PS)</strong> – 0 to 1</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Karnofsky performance status (KPS)</strong> – ≥80</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comorbidities</strong> – To assess the significance of comorbid conditions, we use the hematopoietic cell transplantation specific comorbidity index (HCT-CI)  (<a class="graphic graphic_table graphicRef59272" href="/d/graphic/59272.html" rel="external">table 3</a>), which was originally designed to predict outcomes in patients undergoing HCT [<a href="#rid3">3</a>].</p><p></p><p>Geriatric consultation can be helpful to assess patients who may be at increased risk for treatment-related complications. Examples include patients with impaired performance status (eg, ECOG PS ≥2, KPS &lt;80), significant comorbidities (eg, HCT-CI ≥3), or age ≥75 years. (See  <a class="medical medical_review" href="/d/html/86177.html" rel="external">"Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults"</a>.)</p><p class="headingAnchor" id="H2793465177"><span class="h1">CLASSIFICATION AND RISK STRATIFICATION</span><span class="headingEndMark"> — </span>AML should be analyzed and categorized using a contemporary classification scheme and the prognosis evaluated.</p><p class="headingAnchor" id="H3771876508"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>Bone marrow aspirate and biopsy should be performed and analyzed with microscopy, cytogenetics, and molecular testing.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microscopy</strong> – The percentage of blasts is determined by counting ≥500 nucleated cells. Myeloblasts, monoblasts, and megakaryoblasts are included in the blast count. Monoblasts and promonocytes but not abnormal monocytes are counted as blast equivalents for cases of AML with monocytic or myelomonocytic differentiation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunophenotype</strong> – Flow cytometry should include markers of hematopoietic precursors, myeloid differentiation and maturation, monocytes, megakaryocytes, erythroid cells, T lymphocytes, and B lymphocytes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytogenetics</strong> – Chromosome banding of ≥20 metaphases is required to define a normal karyotype and is preferred for an abnormal karyotype. Blood specimens with circulating blasts can be used to define the karyotype.</p><p></p><p class="bulletIndent1">If there are no analyzable metaphases, fluorescence in-situ hybridization is acceptable for detecting genetic abnormalities (eg, <em>RUNX1::RUNX1T1, CBFB::MYH11, KMT2A</em>, and <em>MECOM</em> gene fusions) or myelodysplasia-related chromosomal abnormalities (eg, loss of chromosome 5q, 7q, or 17p).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic analysis</strong> – Screening for acquired gene mutations and for inherited gene variants of potential pathogenic significance is required to diagnose and classify AML and to identify actionable therapeutic targets. Gene panel testing is preferred where available.</p><p></p><p class="bulletIndent1">Testing should include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gene rearrangements</strong> – <em>PML::RARA</em>,<em> CBFB::MYH11</em>,<em> RUNX1::RUNX1T1</em>,<em> KMT2A </em>rearrangements,<em> BCR::ABL1</em>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Actionable mutations</strong> – <em>FLT3 </em>(including internal tandem duplications [ITD] and of tyrosine kinase domain [TKD] mutations),<em> IDH1</em>,<em> IDH2</em>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other mutations with prognostic relevance</strong> – <em>NPM1</em>,<em> CEBPA</em>,<em> DDX41</em>,<em> TP53</em>;<em> ASXL1</em>,<em> BCOR</em>,<em> EZH2</em>,<em> RUNX1</em>,<em> SF3B1</em>,<em> SRSF2</em>,<em> STAG2</em>,<em> U2AF1</em>,<em> ZRSR2</em>.</p><p></p><p class="headingAnchor" id="H3942312972"><span class="h2">AML classification</span><span class="headingEndMark"> — </span>Two revised classification schemes for hematologic malignancies were published in 2022. These models differ in important ways from each other and from earlier classification schemes. Examples of important changes include the blast thresholds to diagnose AML, newly defined genetic subtypes, and new labels and organization for certain subtypes of AML:</p><p class="bulletIndent1"><span class="glyph">●</span>International Consensus Classification (ICC) [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>World Health Organization 5<sup>th</sup> edition (WHO5) [<a href="#rid5">5</a>].</p><p></p><p>Both ICC and WHO5 rely heavily on cytogenetic and molecular features of AML, and use of either scheme is preferred over earlier classification models. Details of AML classification are discussed separately. (See  <a class="medical medical_review" href="/d/html/86098.html" rel="external">"Acute myeloid leukemia: Classification"</a>.)</p><p>ICC and WHO5 apply the same criteria for diagnosis of acute promyelocytic leukemia with t(15;17)(q24.1;q21.2)/<em>PML::RARA</em>, which requires distinctive management that differs from treatment of other categories of AML. (See  <a class="medical medical_review" href="/d/html/4527.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults"</a> and  <a class="medical medical_review" href="/d/html/4498.html" rel="external">"Initial treatment of acute promyelocytic leukemia in adults"</a>.)</p><p>ICC and WHO5 apply different labels and diagnostic criteria for certain categories of AML including:</p><p class="bulletIndent1"><span class="glyph">●</span>Secondary AML</p><p class="bulletIndent1"><span class="glyph">●</span>Therapy-related myeloid neoplasms</p><p class="bulletIndent1"><span class="glyph">●</span>Mixed phenotype acute leukemia</p><p class="bulletIndent1"><span class="glyph">●</span>Myeloid neoplasms with germline predisposition</p><p></p><p>Details of AML nosology are presented separately. (See  <a class="medical medical_review" href="/d/html/86098.html" rel="external">"Acute myeloid leukemia: Classification"</a>.)</p><p class="headingAnchor" id="H626893193"><span class="h2">European LeukemiaNet risk stratification</span><span class="headingEndMark"> — </span>The European LeukemiaNet (ELN) stratification scheme uses cytologic and molecular features of the leukemia to categorize prognosis as follows [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Favorable</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>t(8;21)(q22;q22.1)/<em>RUNX1::RUNX1T1</em></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/<em>CBFB::MYH11</em></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mutated <em>NPM1</em> without <em>FLT3</em>-ITD</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>bZIP in-frame mutated <em>CEBPA</em> </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intermediate</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mutated <em>NPM1</em> with <em>FLT3</em>-ITD</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Wild-type <em>NPM1</em> with <em>FLT3</em>-ITD (without adverse-risk genetic lesion)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>t(9;11)(p21.3;q23.3)/<em>MLLT3::KMT2A</em></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cytogenetic and/or molecular abnormalities not classified as favorable or adverse</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>t(6;9)(p23;q34.1)/<em>DEK::NUP214</em></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>t(v;11q23.3)/<em>KMT2A</em>-rearranged</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>t(9;22)(q34.1;q11.2)/<em>BCR::ABL1</em></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>t(8;16)(p11;p13)/<em>KAT6A::CREBBP</em></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/<em>GATA2</em>, <em>MECOM</em> (<em>EVI1</em>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>t(3q26.2;v)/<em>MECOM</em> (<em>EVI1</em>)-rearranged</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>-5 or del(5q); -7; -17/abn(17p)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complex karyotype or monosomal karyotype</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mutated <em>ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, </em>or<em> ZRSR2</em></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mutated <em>TP53</em></p><p></p><p>The ELN prognostic category may influence the choice of induction therapy and it guides postremission management of AML.</p><p class="headingAnchor" id="H1444265767"><span class="h1">INDUCTION THERAPY</span><span class="headingEndMark"> — </span>The backbone of intensive induction therapy for AML is <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> plus an anthracycline. There are several acceptable regimens as discussed below. (See <a class="local">'Initial therapy'</a> below.)</p><p>Special scenarios that may affect selection of induction therapy are discussed below. (See <a class="local">'Special scenarios'</a> below.)</p><p class="headingAnchor" id="H3434065218"><span class="h2">Initial therapy</span><span class="headingEndMark"> — </span>Induction therapy is stratified according to the presence or absence of mutated <em>FLT3</em>:</p><p class="bulletIndent1"><span class="glyph">●</span>(See <a class="local">'AML without mutated FLT3'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See <a class="local">'AML with mutated FLT3'</a> below.)</p><p></p><p class="headingAnchor" id="H2447957605"><span class="h3">AML without mutated <i>FLT3</i></span><span class="headingEndMark"> — </span>For newly diagnosed AML <strong>without</strong> mutated <em>FLT3</em>, we recommend treatment with a seven-day continuous infusion of <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> plus an anthracycline for three days (so-called "7+3 therapy"), based on the favorable balance of outcomes and toxicity.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – The regimen that is most often used is:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cytarabine</strong> – 100 to 200 mg/m<sup>2</sup>/day by continuous intravenous (IV) infusion for days 1 to 7</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anthracycline</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Daunorubicin</strong> – 60 to 90 mg/m<sup>2</sup> IV on days 1 to 3</p><p></p><p class="bulletIndent3">or</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Idarubicin</strong> – 12 mg/m<sup>2</sup> IV on days 1 to 3</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Treatment with "7+3 therapy" generally causes three to five weeks of profound cytopenias with a risk of life-threatening infections and bleeding. Many patients will experience nausea and vomiting, mucositis/stomatitis, alopecia, and diarrhea. <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">Cytarabine</a> may cause a flu-like syndrome (including fever and/or rash), and <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a> can be associated with infusion reactions and cardiac arrhythmias. These and other adverse effects (AEs) are discussed in more detail separately. (See <a class="local">'Adjunctive care'</a> below and  <a class="medical medical_review" href="/d/html/2835.html" rel="external">"Infusion reactions to systemic chemotherapy", section on 'Anthracyclines and related agents'</a> and  <a class="medical medical_review" href="/d/html/2835.html" rel="external">"Infusion reactions to systemic chemotherapy", section on 'Cytarabine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Regimens using <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> plus anthracycline have been standard induction therapy for AML for many years. Randomized trials that examined the dose, schedule, and choice of agents in "7+3 therapy" reported similar outcomes using cytarabine plus either <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a>, <a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a>, or the anthracenedione <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>. Replacement of infusional cytarabine by high-dose cytarabine (HiDAC) was associated with increased toxicity without improved efficacy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Daunorubicin</strong><strong> dose</strong> – Higher doses of <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a> (eg, 60 mg/m<sup>2</sup> or 90 mg/m<sup>2</sup>) are more efficacious but not more toxic compared with daunorubicin 45 mg/m<sup>2</sup>.</p><p></p><p class="bulletIndent2">A systematic review and meta-analysis that included 29 randomized trials reported that higher-dose <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a> was associated with reduced rates for remission failure (relative risk [RR] 0.75; 95% CI 0.60-0.94) and overall mortality (RR 0.83; 95% CI 0.75-0.93) but similar rates of early death [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent2">In the Eastern Cooperative Oncology Group (ECOG) 1900, 330 patients &lt;60 years old with favorable/intermediate-risk AML were randomly assigned to treatment with <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a> 90 mg/m<sup>2 </sup>versus<sup> </sup>45 mg/m<sup>2</sup> [<a href="#rid8">8</a>]. Compared with the lower dose, higher-dose daunorubicin achieved superior median overall survival (OS; 34 versus 21 months) and more complete remissions (CR; 71 versus 57 percent); both trial arms had similar rates of grade ≥3 AEs, including cardiac and hematopoietic toxicity.</p><p></p><p class="bulletIndent2">Other randomized trials evaluated <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a> 90 mg/m<sup>2</sup> in AML induction therapy. Compared with 45 mg/m<sup>2</sup>, the 90 mg/m<sup>2</sup> dose achieved superior five-year OS (47 versus 35 percent) and CR (83 versus 72 percent) [<a href="#rid9">9</a>]. In another randomized trial, OS, relapse-free survival, CR, and AEs were similar with daunorubicin 90 mg/m<sup>2</sup> versus 60 mg/m<sup>2</sup> [<a href="#rid10">10</a>]; however, retrospective analysis of this trial reported that the higher dose of daunorubicin was associated with improved outcomes only for the subset of patients with<em> FLT3 </em>mutation [<a href="#rid11">11</a>], as described below. (See <a class="local">'AML with mutated FLT3'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Daunorubicin</strong><strong> versus </strong><strong>idarubicin</strong> – <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">Daunorubicin</a> and <a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a> are associated with similar outcomes.</p><p></p><p class="bulletIndent2">A systematic review and meta-analysis reported no difference between <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a> and <a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a> with regard to overall mortality or early death [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent2">The three-arm Acute Leukemia French Association (ALFA)-9801 trial randomly assigned 468 patients 50 to 70 years old to <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a> 80 mg/m<sup>2</sup> once daily for three days versus <a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a> 12 mg/m<sup>2</sup> once daily for three days versus idarubicin 12 mg/m<sup>2</sup> once daily for four days; rates of CR were 70, 83, and 78 percent, respectively, but OS, event-free survival (EFS), and relapse incidence did not differ between arms [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cytarabine</strong><strong> dose</strong> – Comparable outcomes and toxicity were achieved with a seven-day continuous infusion of <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> 100 mg/m<sup>2</sup>/day versus cytarabine 200 mg/m<sup>2</sup>/day [<a href="#rid13">13</a>]. Compared with HiDAC plus an anthracycline, "7+3 therapy" using either dose of infusional cytarabine achieved similar outcomes but less toxicity [<a href="#rid14">14-16</a>].</p><p></p><p>There is no evidence that alternative induction regimens are associated with better outcomes or less toxicity than "7+3 therapy" in this setting, as discussed below. (See <a class="local">'Alternative induction regimens'</a> below.)</p><p>For patients with secondary AML, therapy-related AML, or adverse cytogenetic features, some experts favor induction using CPX-351 (liposome-encapsulated <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> plus <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a>), as discussed below. (See <a class="local">'Secondary and therapy-related AML'</a> below.)</p><p>For CD33-positive AML with intermediate or favorable cytogenetic features, some experts add <a class="drug drug_general" data-topicid="8968" href="/d/drug information/8968.html" rel="external">gemtuzumab ozogamicin</a> (GO) to "7+3 induction therapy," as discussed below. (See <a class="local">'Gemtuzumab ozogamicin'</a> below.)</p><p class="headingAnchor" id="H2398079087"><span class="h3">AML with mutated <i>FLT3</i></span><span class="headingEndMark"> — </span>For patients with <em>FLT3</em>-mutated AML, we recommend addition of either <a class="drug drug_general" data-topicid="112991" href="/d/drug information/112991.html" rel="external">midostaurin</a> (for any <em>FLT3</em> mutation) or <a class="drug drug_general" data-topicid="142055" href="/d/drug information/142055.html" rel="external">quizartinib</a> (for <em>FLT3</em> with internal tandem repeats [ITD]) to intensive induction chemotherapy.  </p><p>●<strong>Administration</strong></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Midostaurin</strong> – Administered orally 50 mg twice daily on days 8 through 21. <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">Cytarabine</a> and an anthracycline are administered, as described above. (See <a class="local">'AML without mutated FLT3'</a> above.)</p><p></p><p class="bulletIndent2">Strong CYP3A4 activators and inhibitors may alter exposure to <a class="drug drug_general" data-topicid="112991" href="/d/drug information/112991.html" rel="external">midostaurin</a> and its active metabolites; alternatives to agents that strongly affect CYP3A4 should be considered.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Quizartinib</strong> – Administered 35.4 mg orally once daily on days 8 to 21 of "7+3" therapy. </p><p></p><p class="bulletIndent2">A boxed warning for <a class="drug drug_general" data-topicid="142055" href="/d/drug information/142055.html" rel="external">quizartinib</a> notes QT prolongation, torsades de pointes, and cardiac arrest. The QT interval should be assessed prior to initiating quizartinib and periodically during treatment. Hypokalemia and hypomagnesemia should be corrected. Treatment should not be initiated if the QT interval (corrected by Fridericia's formula [QTcF]) is &gt;450 ms. The dose of quizartinib should be reduced when used concomitantly with strong CYP3A inhibitors.</p><p></p><p class="bulletIndent1">The US Food and Drug Administration (FDA) and the European Medicines Agency approved <a class="drug drug_general" data-topicid="112991" href="/d/drug information/112991.html" rel="external">midostaurin</a> in combination with chemotherapy for newly diagnosed AML with mutated<em> FLT3</em> in adults. The FDA approved <a class="drug drug_general" data-topicid="142055" href="/d/drug information/142055.html" rel="external">quizartinib</a> in combination with "7+3" induction therapy for AML that is positive for<em> FLT3</em>-ITD but not for other<em> FLT3</em> mutations; quizartinib is available only through a Risk Evaluation and Mitigation Strategy (REMS) in the US [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – In phase 3 trials that compared either <a class="drug drug_general" data-topicid="112991" href="/d/drug information/112991.html" rel="external">midostaurin</a> or <a class="drug drug_general" data-topicid="142055" href="/d/drug information/142055.html" rel="external">quizartinib</a> versus placebo as components of induction therapy, there were similar rates of grade ≥3 febrile neutropenia, infections, nausea, and mucositis in both treatment arms [<a href="#rid18">18-20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Midostaurin</strong> – In the CALGB 10603/RATIFY trial, 717 adults (&lt;60 years) who had AML w<em>ith FLT3-</em>internal tandem duplications (<em>ITD; </em>77 percent<em>) or FLT3-</em>tyrosine kinase domain (TKD) mutations (23 percent) were randomly assigned to 7+3 chemotherapy plus either <a class="drug drug_general" data-topicid="112991" href="/d/drug information/112991.html" rel="external">midostaurin</a> or placebo [<a href="#rid18">18</a>]. With median follow-up of 59 months compared with placebo, midostaurin achieved superior median OS (75 versus 26 months), four-year OS (51 versus 44 percent), median EFS (8 versus 3 months), and four-year EFS (28 versus 21 percent). The two trial arms had similar rates of CR, time to recovery of neutrophils and platelets, grade ≥3 toxicity, and treatment-related deaths.</p><p></p><p class="bulletIndent2">A phase 2 study reported that addition of <a class="drug drug_general" data-topicid="112991" href="/d/drug information/112991.html" rel="external">midostaurin</a> to 7+3 chemotherapy was also beneficial in older patients (61 to 70 years) [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Quizartinib</strong> – Addition of <a class="drug drug_general" data-topicid="142055" href="/d/drug information/142055.html" rel="external">quizartinib</a> to "7+3" induction therapy achieved better survival than adding placebo to "7+3" therapy, among 539 patients wi<em>th FLT3</em> ITD-positive AML in the phase 3 QuANTUM-First trial [<a href="#rid20">20</a>].Patients subsequently received consolidation with HiDAC plus either quizartinib or placebo, allogeneic hematopoietic cell transplantation (HCT), or both, followed by continuation of single-agent quizartinib or placebo for up to three years. Median OS was 32 months with quizartinib compared with 15 months with placebo (HR 0.78 [95% CI 0.62-0.98]). The most common grade ≥3 AEs were febrile neutropenia, hypokalemia, and pneumonia in both groups and neutropenia in the quizartinib group; at least one grade ≥3 AE occurred in approximately 90 percent of patients in both arms.</p><p></p><p class="headingAnchor" id="H793869071"><span class="h2">Nadir response assessment</span><span class="headingEndMark"> — </span>Bone marrow examination is performed at the hematologic nadir (usually day 14 to 22). For patients receiving <a class="drug drug_general" data-topicid="112991" href="/d/drug information/112991.html" rel="external">midostaurin</a> (days 8 to 21), the nadir assessment should be performed on day 22. Further management is guided by the findings:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypoplasia</strong> – For bone marrow that reveals hypoplasia (ie, &lt;20 percent cellularity) and clearance of blasts (ie, &lt;5 percent of residual cellularity), monitoring of blood counts and adjunctive care continues until recovery of blood counts. (See <a class="local">'Adjunctive care'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent blasts</strong> – For bone marrow that is not hypoplastic and/or has blasts ≥5 percent, a second cycle of induction therapy should be administered without delay if the patient can tolerate it. (See <a class="local">'Reinduction (second attempt)'</a> below.)</p><p></p><p>If the findings from the nadir study are ambiguous, a bone marrow examination should be repeated five to seven days later.</p><p class="headingAnchor" id="H692575426"><span class="h2">Reinduction (second attempt)</span><span class="headingEndMark"> — </span>For patients with persistent AML on the nadir bone marrow examination, we suggest reinduction therapy rather than observation.</p><p>Reinduction generally uses <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, with or without an anthracycline or other agents, but doses and schedules vary among institutions, and there is no consensus.</p><p>Examples of reinduction regimens include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repeat treatment with an anthracycline plus infusional </strong><strong>cytarabine</strong> – Various protocols have been used for reinduction, including repeat treatment with "7+3" or variants of the initial induction regimen. (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent1">In some settings, reinduction may include a shorter course (eg, five days of <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> infusion plus two days of an anthracycline) and/or a lower dose of the anthracycline (eg, <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a> 45 mg/m<sup>2</sup> or <a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a> 10 mg/m<sup>2</sup>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other </strong><strong>cytarabine</strong><strong>-based treatment</strong> – An intermediate-dose cytarabine-containing regimen (eg, FLAG [<a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, and granulocyte colony-stimulating factor (G-CSF)]) or HiDAC alone may be used for reinduction.</p><p></p><p class="bulletIndent1">HiDAC is generally limited to patients ≤60 years because of the increased risk of neurotoxicity in older patients, and the dose may be adjusted based on renal function. (See  <a class="medical medical_review" href="/d/html/4533.html" rel="external">"Acute myeloid leukemia in younger adults: Post-remission therapy", section on 'Administration of consolidation HiDAC'</a>.)</p><p></p><p>For older patients with residual disease or those who cannot tolerate another course of anthracycline/<a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, some clinicians switch to a hypomethylating agent plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a>, based on efficacy in previously untreated older patients with AML and relapsed/refractory disease [<a href="#rid22">22-25</a>].</p><p class="headingAnchor" id="H3005991775"><span class="h1">REMISSION STATUS</span><span class="headingEndMark"> — </span>The response to induction therapy is determined by evaluation of bone marrow, blood, and/or extramedullary sites (if involved) after recovery of hematopoiesis.</p><p class="headingAnchor" id="H941028514"><span class="h2">Response evaluation</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone marrow</strong> – Bone marrow aspirate and biopsy is performed when the absolute neutrophil count (ANC) is ≥1 x 10<sup>9</sup>/L (≥1000/microL) and platelet count is ≥100 x 10<sup>9</sup>/L (≥100,000/microL). This is generally four or more weeks after starting induction therapy, although the timing varies according to whether the patient received one or two cycles of induction therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extramedullary involvement</strong> – For patients with central nervous system (CNS) involvement at diagnosis, the CNS should also be reevaluated with imaging and/or lumbar puncture, as discussed separately. (See  <a class="medical medical_review" href="/d/html/4521.html" rel="external">"Involvement of the central nervous system (CNS) with acute myeloid leukemia (AML)"</a>.)</p><p></p><p class="bulletIndent1">Similarly, patients with extramedullary tumor masses (ie, myeloid sarcoma) should have post-therapy imaging and if necessary, biopsy, to confirm remission.</p><p></p><p class="headingAnchor" id="H2909786924"><span class="h2">Remission criteria</span><span class="headingEndMark"> — </span>Following are remission criteria; note that outcomes are modified to incorporate measurable residual disease (MRD) status if evaluated.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete remission (CR)</strong> – Bone marrow blasts &lt;5 percent and none with Auer rods; no circulating blasts or blasts with Auer rods; absence of extramedullary disease; ANC ≥1 x 10<sup>9</sup>/L (≥1000/microL); platelet count ≥100 x 10<sup>9</sup>/L (100,000/microL)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CR with partial hematologic recovery (CRh)</strong> – ANC ≥0.5 x 10<sup>9</sup>/L and platelet count ≥50 x 10<sup>9</sup>/L; all other CR criteria are met.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CR with incomplete hematologic recovery (CRi)</strong> – CRi can be used to describe patients who meet all CR criteria except for residual neutropenia (&lt;1 x 10<sup>9</sup>/L) or thrombocytopenia (platelets &lt;100 x 10<sup>9</sup>/L).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory AML</strong> – Not meeting criteria for CR, CRh, or CRi after two cycles of intensive induction therapy.</p><p></p><p class="headingAnchor" id="H2914731950"><span class="h2">Measurable residual disease</span><span class="headingEndMark"> — </span>MRD can provide a quantitative method to define a deeper remission than morphologic criteria alone, and it can refine postremission relapse risk assessment and identify impending relapse.</p><p>MRD has prognostic value for overall survival (OS) and relapse based on a systematic meta-analysis and various studies [<a href="#rid26">26-31</a>]. However, a negative assay simply indicates that disease is below the threshold of the assay; it does not indicate complete eradication of the leukemia, since relapse can still occur in a small minority of MRD-negative patients, and conversely, not all MRD-positive patients inevitably relapse.</p><p>Multiparameter flow cytometry (MFC) and quantitative polymerase chain reaction (qPCR) are the most common methods for assessing MRD [<a href="#rid32">32</a>]. Next-generation sequencing (NGS) and digital PCR are emerging technologies for assessing MRD, but they are not currently standard approaches in clinical practice [<a href="#rid33">33</a>]. The preferred technique varies among institutions and with pathologic aspects of the case. MFC is more broadly applicable (eg, up to 90 percent of cases), but it is slightly less sensitive than qPCR, which is applicable in up to one-half of cases of AML [<a href="#rid6">6</a>].</p><p>Standards for MRD analysis, MRD thresholds, and definitions of MRD response have been published [<a href="#rid34">34</a>].</p><p>For patients with CR or CRh with negative MRD, the outcome can be labeled CR<sub>MRD-</sub> or CRh<sub>MRD-</sub>, respectively.</p><p class="headingAnchor" id="H2547788574"><span class="h3">MRD by multiparameter flow cytometry</span><span class="headingEndMark"> — </span>Multiparameter flow cytometry (MFC) is the most common method for assessing MRD in clinical practice. It can be used in nearly all cases of AML, and it provides sensitivity of 10<sup>-3</sup> to 10<sup>-4</sup>.</p><p>Persistent blasts are distinguished from normal hematopoietic cells according to a leukemia-associated immunophenotype or a "different from normal" immunophenotype. MFC evaluation for leukemic stem cells is investigational and not widely used in clinical practice.</p><p>A set of "core" markers should include: CD34, CD117, CD45, CD33, CD13, CD56, CD7, and HLA-DR. If the blasts exhibit monocytic features, CD64, CD11b, and CD4 should be added.</p><p class="headingAnchor" id="H4108510580"><span class="h3">Molecular MRD</span><span class="headingEndMark"> — </span>Polymerase chain reaction (PCR) can detect MRD in blood or bone marrow. The sensitivity is 10<sup>-4</sup> to 10<sup>-5</sup> in marrow, but it is generally one order of magnitude less sensitive in blood.</p><p>Leukemia-related abnormalities that are suitable for qPCR monitoring include mutated <em>NPM1</em>; <em>CBFB::MYH11, RUNX1::RUNX1T1, KMT2A::MLLT3, DEK::NUP214, </em>and<em> BCR::ABL1</em> gene fusions; and <em>WT1</em> expression [<a href="#rid34">34</a>]. Detection of MRD by qPCR has been best validated with AML that has <em>NPM1</em> mutation, <em>CBFB::MYH11</em>, or <em>RUNX1::RUNX1T1 </em>[<a href="#rid35">35</a>].</p><p>MRD detection by NGS is not broadly used in clinical practice. If used, error-corrected targeted panel-based approaches are preferred. Care must be taken to recognize and exclude germline mutations (eg, <em>DDX41</em>) or mutations associated with preexisting clonal hematopoiesis of indeterminate potential (CHIP; eg, <em>DNMT3A, TET2, ASXL1</em>), as these are not considered to reflect MRD for AML [<a href="#rid36">36</a>]. </p><p class="headingAnchor" id="H2824993323"><span class="h1">ADJUNCTIVE CARE</span><span class="headingEndMark"> — </span>Patients undergoing intensive remission induction therapy require careful monitoring and adjunctive care for manifestations of the underlying leukemia and treatment-associated complications. Induction therapy generally causes three to five weeks of profound cytopenias and may cause life-threatening infections, organ dysfunction, and other complications.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical</strong> <strong>monitoring</strong> – The patient should be examined at least daily for infusion reactions, tumor lysis syndrome (TLS; especially with high blast counts), nausea/vomiting, mucositis, diarrhea, infections, and other complications of therapy. It is important to recognize that clinical findings of infection may be blunted or absent during periods of profound neutropenia. Careful attention is paid to fluid balance and daily weights, and diuretics may be necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory studies</strong> – We perform the following laboratory studies:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Complete blood count with differential</strong> – Complete blood count (CBC) with differential count should be performed daily until recovery of white blood cell count to ≥500/microL and platelet transfusion independence is achieved. The frequency of CBCs can then be reduced (eg, to every other day), as clinically appropriate.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Coagulation studies</strong> – Prothrombin time/international normalized ratio and partial thromboplastin should be monitored at least weekly or more frequently if clinically indicated. Fibrinogen should be measured early in remission induction because disseminated intravascular coagulation (DIC) can be triggered by chemotherapy. Patients with clinical or laboratory evidence of DIC, serum fibrinogen, fibrin degradation products (FDPs), and/or other tests should be monitored at least daily until DIC has resolved. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chemistry profile</strong> – Chemistry profile, including electrolytes, blood urea nitrogen (BUN), creatinine, uric acid, calcium, phosphorus, and liver function tests, including lactate dehydrogenase, should be performed at least daily until the risk of TLS has passed. The frequency of testing can then be adjusted as clinically appropriate. Close monitoring of BUN and creatinine may be required throughout the hospitalization for patients who are receiving nephrotoxic agents, such as certain antibiotics. Elevated serum lysozyme levels may lead to renal tubule damage/dysfunction in patients with monocytic/monoblastic leukemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptom management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nausea/vomiting and other gastrointestinal toxicity</strong> – Effective management of nausea and vomiting enhances patient comfort, improves oral hydration and nutritional status, and can reduce the risk of gastrointestinal bleeding or a Mallory-Weiss tear from forceful vomiting.</p><p></p><p class="bulletIndent2">Management of severe nausea and vomiting is described separately. (See  <a class="medical medical_review" href="/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults", section on 'Induction therapy for acute leukemia'</a>.)</p><p></p><p class="bulletIndent2">Induction chemotherapy can damage gastrointestinal epithelial cells and cause painful oral mucositis and diarrhea. Pain may also limit the ability to take oral fluids and nutrition, exacerbating fluid imbalances and impaired nutrition. Breakdown of the mucosal barrier predisposes to viral, bacterial, and fungal (mostly <em>Candida albicans</em>) superinfection, particularly as the hematologic nadir is reached. Management of chemotherapy-induced mucositis and diarrhea are presented separately. (See  <a class="medical medical_review" href="/d/html/1152.html" rel="external">"Oral toxicity associated with systemic anticancer therapy", section on 'Treatment of established mucositis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cytopenias</strong> – Profound and prolonged cytopenias are universal with intensive remission induction therapy, and transfusion of red blood cells (RBCs) and platelets should be provided as needed. Granulocyte colony-stimulating factor (G-CSF; <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a>) and other myeloid growth factors are not routinely administered.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Transfusions</strong> – There is no consensus threshold for transfusion of RBCs or platelets. We generally transfuse RBCs when the patient has anemia-associated symptoms (eg, profound fatigue, dyspnea) and aim to maintain the hemoglobin ≥7 g/dL, but this may vary with age, symptoms, comorbid conditions, and institutional approach. We transfuse platelets prophylactically for patients with platelet counts &lt;10,000/microL or for overt bleeding, such as oral purpura. For patients who are not bleeding, there is no benefit in transfusing multiple platelet units beyond a single platelet pheresis unit daily [<a href="#rid37">37,38</a>]. (See  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults"</a> and  <a class="medical medical_review" href="/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks", section on 'Leukemia, chemotherapy, and HSCT'</a>.)</p><p></p><p class="bulletIndent3">All patients should receive leukoreduced blood products to decrease febrile nonhemolytic transfusion reactions, alloimmunization, and other complications. Irradiated blood products are required for individuals who may be candidates for hematopoietic cell transplantation (HCT) to prevent transfusion-associated graft-versus-host disease (ta-GVHD). For cytomegalovirus (CMV)-negative patients who are candidates for HCT, blood products should be leukoreduced or from CMV-negative donors. (See  <a class="medical medical_review" href="/d/html/7939.html" rel="external">"Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Pre-storage leukoreduction'</a> and  <a class="medical medical_review" href="/d/html/7928.html" rel="external">"Transfusion-associated graft-versus-host disease"</a>.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Growth factors</strong> – In a randomized trial, G-CSF hastened neutrophil recovery but did not lead to differences in the number, severity, or duration of infections [<a href="#rid39">39</a>]. Treatment with G-CSF has been reported to have variable but uncertain effects on the rate of relapse and/or survival in subsets of patients with AML [<a href="#rid40">40-43</a>]. Long-term safety of myeloid growth factors for patients with AML is undefined.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fever/infection</strong> – Prevention of infections is critical given the substantial morbidity and mortality in these patients. The prolonged and profound neutropenia associated with induction therapy is frequently accompanied by fever, a high risk of bacterial or fungal infection, and viral reactivation. Even though most infections during induction therapy are due to endogenous flora, precautions should be taken to limit exposure to exogenous pathogens.</p><p></p><p class="bulletIndent2">Fever or other infectious findings in a neutropenic patient require prompt evaluation and administration of empiric, broad-spectrum parenteral antibiotics. The choice of antibiotics should be tailored to the most likely organisms and institutional drug resistance patterns. (See  <a class="medical medical_review" href="/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>General measures</strong> – Careful hand hygiene, prohibition against sick visitors, and other precautions are used to limit infections. Most methods to reduce the risk of infection have not been rigorously tested but are applied because they are relatively simple and may reduce exposure to potential pathogens. (See  <a class="medical medical_review" href="/d/html/1153.html" rel="external">"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults", section on 'General precautions'</a>.)</p><p></p><p class="bulletIndent3">No benefit was reported from implementation of a "neutropenic diet" (ie, elimination of raw fruits and vegetables) on survival or infections, according to a meta-analysis and randomized trials [<a href="#rid44">44-46</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Prophylaxis</strong> – There is no consensus for use and/or choice of prophylactic antibiotics, antifungals, and antiviral agents during remission induction therapy. Some institutions administer prophylactic fluoroquinolones and/or antifungals, but the potential benefit varies according to the local flora and results of surveillance cultures and must be weighed against the risk of selecting for drug-resistant organisms [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent3">The American Society of Clinical Oncology and the Infectious Disease Society of America recommend that severely neutropenic patients undergoing intensive chemotherapy receive prophylactic antibacterial and antifungal therapy and that patients who are seropositive for hepatitis B core antibody or herpes simplex virus with leukemia receive antiviral prophylaxis [<a href="#rid48">48,49</a>]. Management of antimicrobial prophylaxis is discussed separately. (See  <a class="medical medical_review" href="/d/html/1153.html" rel="external">"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults"</a> and  <a class="medical medical_review" href="/d/html/16141.html" rel="external">"Prophylaxis of invasive fungal infections in adults with hematologic malignancies"</a>.)</p><p></p><p class="headingAnchor" id="H2580706733"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>Most medically fit patients who achieve complete remission after induction therapy proceed to postremission management and subsequent monitoring for relapse and treatment-related complications, as described separately. (See  <a class="medical medical_review" href="/d/html/4540.html" rel="external">"Treatment of relapsed or refractory acute myeloid leukemia"</a>.)</p><p>For patients who do proceed to postremission therapy, there is no consensus about timing of follow-up bone marrow examinations. If the complete blood count remains normal, it is reasonable to repeat a bone marrow examination two to three months after the completion of treatment, since most relapses are signaled by a decline in the platelet count or the appearance of leukemic blasts in the blood smear.</p><p class="headingAnchor" id="H1889987203"><span class="h1">ALTERNATIVE INDUCTION REGIMENS</span></p><p class="headingAnchor" id="H1451359269"><span class="h2">FLAG-Ida</span><span class="headingEndMark"> — </span>FLAG-Ida (<a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, G-CSF [granulocyte colony-stimulating factor], <a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a>) is used by some experts for patients with intermediate or adverse prognosis AML.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – FLAG-Ida consists of intravenous (IV) <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a> 30 mg/m<sup>2</sup> on days 2 to 6, high-dose <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> (HiDAC; 1500 to 2000 mg/m<sup>2</sup> IV over three hours starting four hours after fludarabine infusion on days 2 to 6), <a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a> 10 mg/m<sup>2</sup> IV on days 2 to 4, and G-CSF 5 microg/kg subcutaneously on days 1 to 5. Additional G-CSF may be administered starting on seven days after the end of chemotherapy until the white blood cell count is &gt;500/microL.</p><p></p><p class="bulletIndent1">The following dose adjustments should be considered for patients &gt;60 years: <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a> 20 mg/m<sup>2</sup>, <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> 500 to 1000 mg/m<sup>2</sup>, and <a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a> 8 mg/m<sup>2</sup>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – There is no evidence that FLAG-Ida is associated with better outcomes than induction with <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>/anthracycline.</p><p></p><p class="bulletIndent1">In the MRC AML 15 trial, younger patients (median 49 years) were randomly assigned to FLAG-Ida versus two induction courses of <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a>/<a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, with or without <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>; patients receiving FLAG-Ida or daunorubicin/cytarabine (without etoposide) were also randomly assigned to receive a single dose of <a class="drug drug_general" data-topicid="8968" href="/d/drug information/8968.html" rel="external">gemtuzumab ozogamicin</a> (GO) during the first induction cycle [<a href="#rid50">50</a>]. Patients were then randomly assigned to different consolidation regimens (HiDAC versus <a class="drug drug_general" data-topicid="9343" href="/d/drug information/9343.html" rel="external">amsacrine</a>, cytarabine, etoposide, then <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>/cytarabine). There was no difference in complete remission (CR) rate between patients who received induction therapy with FLAG-Ida versus daunorubicin/cytarabine/etoposide (84 versus 81 percent, respectively), but FLAG-Ida was associated with a decreased relapse rate (38 versus 55 percent).</p><p></p><p class="headingAnchor" id="H3455112754"><span class="h2">CPX-351</span><span class="headingEndMark"> — </span>CPX-351 is a liposomal formulation that encapsulates <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>/<a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a> in a 5:1 fixed molar ratio [<a href="#rid51">51</a>]. Treatment with CPX-351 for secondary AML and therapy-related AML is discussed below. (See <a class="local">'Secondary and therapy-related AML'</a> below.)</p><p>CPX-351 is given 100 units/m<sup>2</sup> as a 90-minute IV infusion on days 1, 3, and 5. For patients with persistent blasts or without hypoplastic bone marrow on day 14, reinduction (second induction) with the same dose of CPX-351 is given on days 1 and 3.</p><p class="headingAnchor" id="H3717141861"><span class="h2">Gemtuzumab ozogamicin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8968" href="/d/drug information/8968.html" rel="external">Gemtuzumab ozogamicin</a> (GO) is an anti-CD33 monoclonal antibody linked to calicheamicin that has yielded mixed results when added to "7+3 therapy" for CD33-positive AML, but treatment is associated with increased toxicity.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – GO is given IV at 3 mg/m<sup>2</sup> (capped at 5 mg) on days 1, 4, and 7 of induction therapy; a single dose of GO on day 1 of induction may also be efficacious [<a href="#rid52">52-54</a>].</p><p></p><p class="bulletIndent1">Various doses and schedules have been used when combining GO with chemotherapy, and higher doses appear to be associated with increased risks [<a href="#rid52">52,55</a>].</p><p></p><p class="bulletIndent1">The threshold of CD33 expression for efficacy of GO is not well-defined.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Addition of GO to AML induction therapy was beneficial for certain subsets of patients in a meta-analysis, but individual randomized trials provided mixed results:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A meta-analysis of five studies reported that addition of GO to "7+3 induction therapy" was associated with better outcomes in some prognostic subsets of patients [<a href="#rid52">52</a>]. For patients with favorable- or intermediate-risk cytogenetics, addition of GO to <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>/anthracycline induction therapy was associated with better five-year overall survival (OS) (hazard ratio [HR] 0.90 [95% CI 0.82-0.98]) and reduced risk of relapse (HR 0.81 [95% CI 0.73-0.90]), but it was not associated with more favorable rates of response (CR plus CR with incomplete hematologic recovery [CRi]). No benefit for GO was observed for patients with adverse-risk karyotypes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The multicenter, phase 3 ALFA-0701 trial of 271 patients (age 50 to 70 years) reported superior event-free survival (EFS) (ie, induction failure, relapse, or death) with GO plus "7+3 therapy" compared with "7+3" alone (17 versus 10 months, respectively; HR 0.56 [95% CI 0.42-0.76]), but there was no difference in OS [<a href="#rid56">56,57</a>]. In a follow-up study, the benefit of GO was limited to patients with favorable- or intermediate-risk cytogenetic findings and those with <em>FLT3 </em>or<em> KRA</em>S mutations [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A trial (AMLSG 09-09) that randomly assigned 588 patients with <em>NPM1</em>-mutated AML to <a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a>, <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9262" href="/d/drug information/9262.html" rel="external">all-trans retinoic acid</a>, with or without GO, reported that GO was associated with a lower cumulative incidence of relapse and a greater proportion of patients with undetectable measurable residual disease (MRD), but there were more early deaths (10 versus 6 percent), primarily due to infections and no difference in EFS [<a href="#rid59">59,60</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the MRC AML 15 trial, in patients ≤60 years, addition of GO to induction therapy was well tolerated, and there were no differences in relapse-free survival or OS between arms that received or did not receive GO [<a href="#rid53">53</a>]. Benefits were seen in patients with favorable-risk cytogenetics, with a trend toward benefit for those with intermediate-risk cytogenetics.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>GO has been associated with mixed results in older patients with AML. In a trial of older patients with AML (median 67 years), addition of GO to induction therapy using either <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>/anthracycline or <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a>/<a class="drug drug_general" data-topicid="9220" href="/d/drug information/9220.html" rel="external">clofarabine</a> did not improve CR rate or substantially increase toxicity, but it did achieve improved survival and fewer relapses [<a href="#rid54">54</a>]. In another trial, addition of GO provided no benefit, but it was associated with increased toxicity.</p><p></p><p>GO is approved by the US Food and Drug Administration in combination with "7+3 therapy" for treatment of adults with newly diagnosed CD33-positive AML.</p><p>The GO label includes a boxed warning about hepatotoxicity, including severe or fatal hepatic sinusoidal obstruction syndrome (also called veno-occlusive disease). Other toxicities include infusion-related reactions (including anaphylaxis), hemorrhage, and teratogenicity.</p><p class="headingAnchor" id="H2919197162"><span class="h2">Other regimens</span><span class="headingEndMark"> — </span>There is no conclusive evidence that other induction regimens are superior to "7+3 therapy." As an example, a phase 3 trial reported comparable rates of CR (approximately 80 percent) using the following three regimens: <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> and <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a>; <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, cytarabine, and daunorubicin; or FLAG (<a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>, cytarabine, and G-CSF) [<a href="#rid50">50</a>].</p><p>Aside from the benefit of adding <a class="drug drug_general" data-topicid="112991" href="/d/drug information/112991.html" rel="external">midostaurin</a> for <em>FLT3</em>-mutated AML and a possible benefit from adding GO for CD33-positive AML, there is no persuasive evidence of benefit from adding other agents to a <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>/anthracycline backbone. Effects of midostaurin and GO are discussed above. (See <a class="local">'AML with mutated FLT3'</a> above and <a class="local">'Gemtuzumab ozogamicin'</a> above.)</p><p>Examples of other AML induction regimens include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mitoxantrone</strong><strong>-</strong><strong>cytarabine</strong> – <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">Mitoxantrone</a> is an anthracenedione that has been used in place of an anthracycline for induction therapy. Mitoxantrone 12 mg/m<sup>2</sup> IV on days 1, 2, and 3 (replacing an anthracycline) is given along with a seven-day <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> infusion. (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent1">There is no evidence that mitoxantrone-based induction is more effective or less toxic than an anthracycline for induction therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The AML-10 trial randomly assigned 2157 patients with AML to <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> and <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> plus either <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a>, <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>, or <a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a> [<a href="#rid61">61</a>]. This EORTC/GIMEMA (European Organisation for Research and Treatment of Cancer/Gruppo Italiano Malattie Ematologiche dell’Adultorate) trial reported that the rate of CR was similar in all three trial arms. Long-term survival was inferior for patients who received induction therapy with daunorubicin compared with mitoxantrone or idarubicin, but this finding was confounded by different rates of transplantation between trial arms.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other trials that compared <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a> with <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a> for induction therapy also did not indicate that mitoxantrone was associated with a greater benefit than anthracyclines [<a href="#rid62">62-67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other third agents</strong> – None of the following agents have proven benefit when added to AML induction therapy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Venetoclax</strong> – A phase 2 study of 33 patients reported that adding <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> 100 mg on day 4, 200 mg on day 5, and 400 mg on days 6 to 11 to "7+3 therapy" was associated with CR<sub>MRD-</sub> (CR with undetectable MRD) in 97 percent [<a href="#rid68">68</a>]. Grade ≥3 adverse effects (AEs) included neutropenia, thrombocytopenia, and anemia in 100 percent of patients, febrile neutropenia in 55 percent, pneumonia in 21 percent, and sepsis in 12 percent; there were no treatment-related deaths. Estimated one-year OS and EFS were 97 and 72 percent, respectively.</p><p></p><p class="bulletIndent2">Addition of <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> to FLAG-Ida in 45 patients was associated with 89 percent composite CR (ie, CR, CR with partial hematologic recovery [CRh], and CR with incomplete hematologic recovery [CRi]), including 82 percent with negative MRD; estimated 24-month OS and EFS were 76 and 64 percent, respectively [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent2">We await results of an ongoing phase 3 HOVON/AMLSG of induction and consolidation chemotherapy with <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cladribine</strong> – Addition of the purine analog, <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> (2-CdA), to "7+3 therapy" was associated with improved survival and response rate in two randomized trials, but the results should be further validated before using this regimen in clinical practice.</p><p></p><p class="bulletIndent2">In a randomized trial of 652 adults with AML, compared with "7+3" alone, <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> plus "7+3" achieved superior OS (45 versus 33 percent, respectively) and CR (68 versus 56 percent, respectively) [<a href="#rid70">70</a>]. However, these findings should be independently validated because of the relatively low rates of CR (56 percent) and median OS (14 months) in the control arm. An earlier phase 3 trial by the same group demonstrated similar benefits for cladribine [<a href="#rid71">71</a>]. Toxicity with the addition of cladribine was similar to that with "7+3 therapy" in other studies.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clofarabine</strong> – A HOVON/SAKK trial evaluated <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>/<a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a> induction with or without <a class="drug drug_general" data-topicid="9220" href="/d/drug information/9220.html" rel="external">clofarabine</a> (10 mg/m<sup>2</sup> on days 1 to 5) in patients with AML (18 to 65 years) [<a href="#rid72">72</a>]. OS and EFS did not differ between trial arms; however, patients treated with clofarabine had fewer relapses but more deaths in remission. Subset analysis reported that patients with European LeukemiaNet intermediate-risk (primarily wild-type <em>NPM1</em>/<em>FLT3</em>-internal tandem duplications [ITD]-negative) clofarabine was associated with improved four-year EFS (40 versus 18 percent for the control arm).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other agents</strong> – Addition of <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="10007" href="/d/drug information/10007.html" rel="external">topotecan</a>, <a class="drug drug_general" data-topicid="9989" href="/d/drug information/9989.html" rel="external">thioguanine</a>, or <a class="drug drug_general" data-topicid="9491" href="/d/drug information/9491.html" rel="external">vorinostat</a> to "7+3 therapy" did not improve outcomes [<a href="#rid62">62,72-82</a>].</p><p></p><p class="headingAnchor" id="H27"><span class="h1">SPECIAL SCENARIOS</span></p><p class="headingAnchor" id="H2259783957"><span class="h2">Emergencies</span><span class="headingEndMark"> — </span>A life-threatening medical emergency may be seen at the time of presentation, or it can emerge during induction therapy. The most common emergencies are:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperleukocytosis</strong> – A white blood cell (WBC) count &gt;100 x 10<sup>9</sup>/L (100,000/microL) is associated with increased mortality during induction therapy due to clinical leukostasis, hemorrhage, neurologic dysfunction, and other complications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical leukostasis</strong> – Clinical manifestations of leukostasis, such as neurologic dysfunction or hypoxia, constitute a medical emergency and require immediate intervention.</p><p></p><p class="bulletIndent1">The patient should be treated with <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> (up to 50 to 60 mg/kg per day to reduce the WBC count to &lt;25 x 10<sup>9</sup>/L) or planned induction therapy should begin promptly. The risk of bleeding increases as perfusion is restored to ischemic capillary beds (eg, in the brain); rigorous platelet transfusion support may be necessary. Other urgent interventions include a restrictive transfusion policy for red blood cells (RBCs) and consideration of leukapheresis and/or <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, as discussed separately. (See  <a class="medical medical_review" href="/d/html/4522.html" rel="external">"Hyperleukocytosis and leukostasis in hematologic malignancies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor lysis syndrome</strong> – Tumor lysis syndrome (TLS) and associated metabolic disorders (eg, hyperkalemia, hyperphosphatemia, hyperuricemia, renal insufficiency) are more common in patients with hyperleukocytosis. Management of TLS is discussed separately. (See  <a class="medical medical_review" href="/d/html/1154.html" rel="external">"Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors"</a> and  <a class="medical medical_review" href="/d/html/17050.html" rel="external">"Tumor lysis syndrome: Prevention and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bleeding/coagulation abnormalities</strong> – Bleeding may be associated with severe thrombocytopenia, disseminated intravascular coagulation (DIC), and other coagulopathies. (See  <a class="medical medical_review" href="/d/html/3538.html" rel="external">"Hematopoietic support after hematopoietic cell transplantation", section on 'Platelets'</a> and  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1">DIC is especially common in patients with acute promyelocytic leukemia, which requires distinctive and urgent management. (See  <a class="medical medical_review" href="/d/html/4527.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults"</a> and  <a class="medical medical_review" href="/d/html/4498.html" rel="external">"Initial treatment of acute promyelocytic leukemia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic abnormalities</strong> – Patients with new or unexplained neurologic findings (eg, headache, confusion, cranial neuropathy) require urgent evaluation.</p><p></p><p class="bulletIndent1">Magnetic resonance imaging (MRI) should be performed urgently for patients with neurologic findings consistent with central nervous system (CNS) bleeding, leptomeningeal disease, and/or mass lesions. Computed tomography (CT) is acceptable if there is a contraindication to MRI (eg, implanted metallic devices).</p><p></p><p class="bulletIndent1">Lumbar puncture (LP) should be performed after bleeding and mass lesions have been excluded and with correction of a coagulopathy or severe thrombocytopenia. Administration of one dose of intrathecal chemotherapy (<a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> or <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>) should be considered at the time of the diagnostic LP.</p><p></p><p class="bulletIndent1">Detailed evaluation of patients with neurologic findings in the setting of newly diagnosed AML is discussed separately. (See  <a class="medical medical_review" href="/d/html/4521.html" rel="external">"Involvement of the central nervous system (CNS) with acute myeloid leukemia (AML)", section on 'Evaluation'</a>.)</p><p></p><p class="bulletIndent1">Management of CNS involvement with AML is discussed separately. (See  <a class="medical medical_review" href="/d/html/4521.html" rel="external">"Involvement of the central nervous system (CNS) with acute myeloid leukemia (AML)"</a>.)</p><p></p><p class="headingAnchor" id="H4007298389"><span class="h2">Limited cardiac function</span><span class="headingEndMark"> — </span>For patients with limited heart function who are otherwise medically fit to receive intensive treatments, non-anthracycline-containing induction regimens may be considered.</p><p>All adults should have an echocardiogram or radionuclide ventriculogram prior to initiating induction therapy. We generally avoid anthracyclines in patients with a baseline left ventricular ejection fraction of &lt;40 percent.</p><p>Alternative, non-anthracycline-containing regimens may be considered. However, remission induction is associated with administration of large amounts of intravenous fluids, and cardiac function must be carefully monitored and managed. The use of anthracyclines in patients with heart disease is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a> and  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a>.)</p><p>There is no consensus for patients who cannot tolerate an anthracycline-based regimen, but options include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> plus <a class="drug drug_general" data-topicid="8797" href="/d/drug information/8797.html" rel="external">azacitidine</a> or <a class="drug drug_general" data-topicid="8855" href="/d/drug information/8855.html" rel="external">decitabine</a> (see  <a class="medical medical_review" href="/d/html/4530.html" rel="external">"Acute myeloid leukemia: Management of medically unfit adults", section on 'HMA plus venetoclax'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>FLAG (<a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, G-CSF [granulocyte colony-stimulating factor]) [<a href="#rid83">83</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CLAG (<a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>, <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, G-CSF) [<a href="#rid84">84,85</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clofarabine-based combinations [<a href="#rid72">72,86-88</a>]</p><p></p><p>Other options for patients with limited cardiac function include targeted agents for actionable mutations (eg, <a class="drug drug_general" data-topicid="8968" href="/d/drug information/8968.html" rel="external">gemtuzumab ozogamicin</a> [GO] for CD33-positive AML, IDH inhibitors for <em>IDH</em> mutations) are discussed separately. (See  <a class="medical medical_review" href="/d/html/4530.html" rel="external">"Acute myeloid leukemia: Management of medically unfit adults"</a>.)</p><p>A retrospective study reported similar outcomes with three regimens (FLAG; <a class="drug drug_general" data-topicid="9220" href="/d/drug information/9220.html" rel="external">clofarabine</a> plus <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>; <a class="drug drug_general" data-topicid="10007" href="/d/drug information/10007.html" rel="external">topotecan</a> plus cytarabine) among 52 patients with de novo or relapsed/refractory AML and limited cardiac function [<a href="#rid89">89</a>]. For de novo AML, the complete remission (CR) rate was 63 percent, while cardiovascular and hematologic adverse effects (AEs) were moderate.</p><p>A retrospective study of FLAG in 40 patients with AML reported 70 percent overall response rate (ORR) and only one death during induction [<a href="#rid90">90</a>]. In a study of FLAG induction in 24 patients ≥60 years, outcomes included 58 percent CR, 16 percent CR with incomplete platelet recovery, 12 percent deaths from infections with neutropenia but no other grade ≥3 AEs or significant mucositis [<a href="#rid91">91</a>]. Addition of low-dose GO to FLAG (FLAG-GO) was effective for AML with core-binding factor (CBF) mutations (eg, AML with inv(16) or t(8;21)) [<a href="#rid92">92</a>]. Among 45 patients (median 48 years) with AML with CBF mutations, three-year overall survival (OS) and relapse-free survival were 85 and 78 percent, respectively, with 91 percent CR and 5 percent induction deaths.</p><p class="headingAnchor" id="H1048267764"><span class="h2">Secondary and therapy-related AML</span><span class="headingEndMark"> — </span>For patients with secondary AML (ie, arising from a prior myeloid neoplasm) or therapy-related AML, we favor CPX-351 induction therapy, but induction using <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>/anthracycline ("7+3") or FLAG-Ida is acceptable.</p><p>Two randomized trials directly compared CPX-351 with other intensive induction regimens for secondary AML, therapy-related AML, or AML with adverse cytogenetic features:</p><p class="bulletIndent1"><span class="glyph">●</span>CPX-351 was superior to <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>/anthracycline ("7+3 therapy") induction in a phase 3 trial of 309 patients with treatment-related or secondary AML or de novo AML with myelodysplasia-related cytogenetic abnormalities [<a href="#rid93">93</a>]. Compared with "7+3 therapy," CPX-351 achieved superior five-year OS (18 versus 10 percent; hazard ratio [HR] 0.70 [95% CI 0.55-0.91]) and longer median OS (nine versus six months). There were 5 percent treatment-related deaths in both cohorts, but there was a trend toward higher 30-day mortality with "7+3 therapy" (11 versus 6 percent). More patients treated with CPX-351 were able to proceed to allogeneic transplantation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was no difference in survival between CPX-351 versus FLAG-Ida in younger adults with AML with adverse cytogenetic features or high-risk myelodysplastic syndromes (MDS); 20 percent of patients had secondary AML, 49 percent had de novo AML, and 30 percent had high-risk MDS [<a href="#rid94">94</a>]. There was no difference in OS (13.3 versus 11.4 months) or event-free survival, but relapse-free survival was longer with CPX-351 (median 22.1 versus 8.4 months; HR 0.58 [95% CI 0.36-0.95]), while there was a trend higher ORR with FLAG-Ida. Grade ≥3 nonhematologic AEs were similar in both arms, but FLAG-Ida was associated with slower recovery of neutrophils and platelets, resulting in longer hospitalizations and increases in intravenous antibiotic use and transfusions.</p><p></p><p>Other aspects of management of therapy-related AML are described separately. (See  <a class="medical medical_review" href="/d/html/122864.html" rel="external">"Therapy-related myeloid neoplasms: Management and prognosis", section on 'Medical therapy'</a>.)</p><p class="headingAnchor" id="H28"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>If AML is detected during the first trimester and requires urgent treatment, immediate termination of pregnancy followed by treatment of the leukemia is advisable, as combination chemotherapy given during this time is associated with an unacceptably high incidence of fetal abnormalities and/or fetal loss [<a href="#rid95">95</a>].</p><p>Management of patients diagnosed later in pregnancy (eg, late in the second trimester or during the third trimester) poses a difficult therapeutic dilemma [<a href="#rid96">96</a>]. If the leukemia is relatively indolent, it is sometimes possible to manage patients conservatively with leukapheresis and/or transfusion, with induction of labor and delivery of a viable fetus as soon as possible. However, the hazard of delayed therapy until delivery may pose a significant risk to the mother, and it is generally difficult or impossible to predict whether the AML will take an indolent course.</p><p>There have been many reports of patients treated with chemotherapy later in their pregnancies, most of whom did not abort [<a href="#rid95">95,97-101</a>]. There have been no reports of leukemia occurring in the children, nor an increased incidence of fetal abnormalities in infants who have been exposed to intensive chemotherapy during the later stages of gestation. A literature review of 160 pregnant patients treated with anthracyclines for a variety of malignancies reported no apparent impact on delivered infants in 73 percent of patients [<a href="#rid95">95</a>]. Unfavorable fetal outcomes included fetal death (9 percent), prematurity (6 percent), and malformations (3 percent).</p><p>Chemotherapeutic agents used for AML induction therapy are potentially teratogenic and may affect fertility; contraception should be used for individuals who are considering pregnancy. As an example, the US Food and Drug Administration label for <a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a> advises contraception for ≥6.5 months after the last dose for females and ≥3.5 months for male partners of fertile females [<a href="#rid102">102</a>]. Patients should seek advice for fertility preservation before treatment when possible.</p><p class="headingAnchor" id="H6905614"><span class="h2">Extramedullary disease</span><span class="headingEndMark"> — </span>Myeloid sarcoma refers to an extramedullary mass of myeloid blasts, and it is sufficient to establish a diagnosis of AML [<a href="#rid4">4,5</a>]. Up to 10 percent of patients with AML have extramedullary involvement (eg, leukemia cutis, myeloid sarcoma) at some point during the disease course. Evaluation of patients with extramedullary AML (with or without evidence of AML in marrow) is similar to that for patients with overt AML [<a href="#rid103">103</a>]. (See  <a class="medical medical_review" href="/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia"</a>.)</p><p>Specific aspects of the evaluation and management of extramedullary disease include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – Imaging can characterize extramedullary involvement, aid in radiation treatment planning, and assess response to therapy [<a href="#rid104">104</a>]. Positron emission tomography/CT may be preferred over CT alone for radiation therapy (RT) planning [<a href="#rid105">105-107</a>]. MRI with gadolinium can be used to assess CNS involvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biopsy</strong> – Patients with suspected extramedullary involvement in a location amenable to biopsy should undergo a biopsy of the involved tissue. (See  <a class="medical medical_review" href="/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia", section on 'Pathologic features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation therapy</strong> – RT can be incorporated into treatment, either before induction chemotherapy (eg, for compression of vital structures) or as consolidation after induction chemotherapy (eg, for persistent extramedullary involvement after chemotherapy). Myeloblasts are radiation sensitive, and doses &gt;20 Gy are generally adequate.</p><p></p><p>Treatment of myeloid sarcoma is like that for other AML. Given the rarity of this condition, there is a paucity of data regarding the role of RT in this setting. Remission induction chemotherapy (with or without RT) achieves survival rates similar to those seen in patients with AML without extramedullary disease [<a href="#rid108">108,109</a>]. Without systemic remission induction chemotherapy, patients presenting with myeloid sarcoma will almost always progress to systemic disease, usually within three to six months [<a href="#rid110">110</a>].</p><p class="headingAnchor" id="H597837801"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116628.html" rel="external">"Society guideline links: Acute myeloid leukemia"</a>.)</p><p class="headingAnchor" id="H989199"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15790.html" rel="external">"Patient education: Acute myeloid leukemia (AML) (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15491.html" rel="external">"Patient education: Leukemia in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/681.html" rel="external">"Patient education: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Acute myeloid leukemia (AML) refers to aggressive malignancies of bone marrow myeloid precursor cells that interfere with production of normal blood cells, causing fatigue, weakness, infection, bleeding, and other symptoms and complications.</p><p></p><p class="bulletIndent1">Diagnosis and classification of AML are discussed separately. (See  <a class="medical medical_review" href="/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment evaluation</strong> – Evaluation includes AML-associated complications/emergencies, performance status  (<a class="graphic graphic_table graphicRef57945" href="/d/graphic/57945.html" rel="external">table 2</a>), medical fitness, and medical comorbidities  (<a class="graphic graphic_table graphicRef59272" href="/d/graphic/59272.html" rel="external">table 3</a>) that might affect tolerance for intensive induction therapy. (See <a class="local">'Pretreatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – AML is categorized using a contemporary classification scheme, and prognosis is estimated using the European LeukemiaNet model. (See <a class="local">'Classification and risk stratification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction therapy</strong> – Induction therapy should begin promptly, but clinical stabilization of emergencies/complications and diagnostic work-up are most important and should not be delayed.</p><p></p><p class="bulletIndent1">Induction therapy is stratified as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>AML without mutated </strong><strong><em>FLT3</em></strong> – For AML <strong>without</strong> mutated <em>FLT3</em>, we recommend treatment with a seven-day continuous infusion of <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> plus an anthracycline for three days ("7+3 therapy") (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>) (see <a class="local">'AML without mutated FLT3'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">Cytarabine</a> 100 to 200 mg/m<sup>2</sup> daily as a continuous infusion for 7 days</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">Daunorubicin</a> 60 to 90 mg/m<sup>2</sup> on days 1 to 3 <strong>or</strong> <a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a> 12 mg/m<sup>2 </sup>on<sup> </sup>days 1 to 3</p><p></p><p class="bulletIndent2">Acceptable alternatives are discussed. (See <a class="local">'Alternative induction regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For AML with mutated </strong><strong><em>FLT3</em></strong> – For patients with <em>FLT3</em>-mutated AML, we recommend addition of either <a class="drug drug_general" data-topicid="112991" href="/d/drug information/112991.html" rel="external">midostaurin</a> (for any <em>FLT3</em> mutation) or <a class="drug drug_general" data-topicid="142055" href="/d/drug information/142055.html" rel="external">quizartinib</a> (for <em>FLT3</em> with internal tandem repeats) to intensive induction chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'AML with mutated FLT3'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response</strong> – Bone marrow examination at hematologic nadir (days 14 to 22) guides further management (see <a class="local">'Nadir response assessment'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypoplasia</strong> – For hypoplasia (ie, &lt;20 percent cellularity) and clearance of blasts (ie, &lt;5 percent) in the nadir marrow, we suggest monitoring until recovery of blood counts (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Adjunctive care'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Persistent blasts</strong> – For persistent blasts and cellularity, we suggest reinduction therapy without delay (when tolerable), rather than observation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Reinduction (second attempt)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Remission status</strong> – Bone marrow, blood, and/or extramedullary sites are evaluated at the time of hematologic recovery; criteria are presented above (see <a class="local">'Remission criteria'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Complete remission</strong></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CR with partial hematologic recovery (CRh)</strong></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CR with incomplete hematologic recovery (CRi)</strong></p><p class="bulletIndent2"><span class="glyph">•</span><strong>No response (refractory AML)</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Measurable residual disease (MRD)</strong> – We assess MRD by multicolor flow cytometry or molecular techniques to refine the remission status and aid selection of postremission management. (See <a class="local">'Measurable residual disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive care</strong> – Monitor for complications and medical needs (eg, transfusions, antimicrobials). (See <a class="local">'Adjunctive care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative induction regimens</strong> – Include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>FLAG-Ida</strong> (<a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, G-CSF [granulocyte colony-stimulating factor], <a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a>) (see <a class="local">'FLAG-Ida'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CPX-351</strong> (liposome-encapsulated <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>/<a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a>) (see <a class="local">'CPX-351'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gemtuzumab ozogamicin</strong> (see <a class="local">'Gemtuzumab ozogamicin'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Special scenarios</strong> – Management of medical emergencies and patients with limited cardiac function, secondary/treatment-related AML, and pregnancy. (See <a class="local">'Special scenarios'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bertoli S, Bérard E, Huguet F, et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood 2013; 121:2618.</a></li><li><a class="nounderline abstract_t">Rollig C, Kramer M, Schliemann C, et al. Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts) 2019; 134 (Supplement_1):13.</a></li><li><a class="nounderline abstract_t">Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106:2912.</a></li><li><a class="nounderline abstract_t">Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140:1200.</a></li><li><a class="nounderline abstract_t">Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022; 36:1703.</a></li><li><a class="nounderline abstract_t">Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022; 140:1345.</a></li><li><a class="nounderline abstract_t">Teuffel O, Leibundgut K, Lehrnbecher T, et al. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol 2013; 161:192.</a></li><li><a class="nounderline abstract_t">Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361:1249.</a></li><li><a class="nounderline abstract_t">Lee JH, Joo YD, Kim H, et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 2011; 118:3832.</a></li><li><a class="nounderline abstract_t">Burnett AK, Russell NH, Hills RK, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 2015; 125:3878.</a></li><li><a class="nounderline abstract_t">Burnett AK, Russell NH, Hills RK, United Kingdom National Cancer Research Institute Acute Myeloid Leukemia Study Group. Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia. Blood 2016; 128:449.</a></li><li><a class="nounderline abstract_t">Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010; 28:808.</a></li><li><a class="nounderline abstract_t">Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 1991; 78:2520.</a></li><li><a class="nounderline abstract_t">Willemze R, Suciu S, Meloni G, et al. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol 2014; 32:219.</a></li><li><a class="nounderline abstract_t">Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer 2006; 107:116.</a></li><li><a class="nounderline abstract_t">Löwenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 2013; 121:26.</a></li><li class="breakAll">Quizartinib tablets, for oral use. US Food and Drug Administration (FDA) approved product information. Revised July 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216993s000lbl.pdf (Accessed on July 21, 2023).</li><li><a class="nounderline abstract_t">Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 2017; 377:454.</a></li><li class="breakAll">Midostaurin capsules. United States prescribing information. Revised April 2017. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf (Accessed on June 07, 2022).</li><li><a class="nounderline abstract_t">Erba HP, Montesinos P, Kim HJ, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401:1571.</a></li><li><a class="nounderline abstract_t">Döhner H, Weber D, Krzykalla J, et al. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. Blood Adv 2022; 6:5345.</a></li><li><a class="nounderline abstract_t">DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 2020; 383:617.</a></li><li><a class="nounderline abstract_t">Aldoss I, Yang D, Aribi A, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica 2018; 103:e404.</a></li><li><a class="nounderline abstract_t">DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 2018; 93:401.</a></li><li><a class="nounderline abstract_t">Labrador J, Saiz-Rodríguez M, de Miguel D, et al. Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience. Cancers (Basel) 2022; 14.</a></li><li><a class="nounderline abstract_t">Ivey A, Hills RK, Simpson MA, et al. Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med 2016; 374:422.</a></li><li><a class="nounderline abstract_t">Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular Minimal Residual Disease in Acute Myeloid Leukemia. N Engl J Med 2018; 378:1189.</a></li><li><a class="nounderline abstract_t">Maiti A, DiNardo CD, Wang SA, et al. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 2021; 5:1876.</a></li><li><a class="nounderline abstract_t">Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol 2013; 31:3889.</a></li><li><a class="nounderline abstract_t">Freeman SD, Hills RK, Virgo P, et al. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations. J Clin Oncol 2018; 36:1486.</a></li><li><a class="nounderline abstract_t">Venditti A, Piciocchi A, Candoni A, et al. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood 2019; 134:935.</a></li><li><a class="nounderline abstract_t">Dillon R, Potter N, Freeman S, Russell N. How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML). Br J Haematol 2021; 193:231.</a></li><li><a class="nounderline abstract_t">Vonk CM, Al Hinai ASA, Hanekamp D, Valk PJM. Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia. Cancers (Basel) 2021; 13.</a></li><li><a class="nounderline abstract_t">Heuser M, Freeman SD, Ossenkoppele GJ, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2021; 138:2753.</a></li><li><a class="nounderline abstract_t">Arber DA, Hasserjian RP, Orazi A, et al. Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach. Am J Hematol 2022; 97:514.</a></li><li><a class="nounderline abstract_t">Heuser M, Heida B, Büttner K, et al. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. Blood Adv 2021; 5:2294.</a></li><li><a class="nounderline abstract_t">Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362:600.</a></li><li><a class="nounderline abstract_t">Schiffer CA, Bohlke K, Delaney M, et al. Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2018; 36:283.</a></li><li><a class="nounderline abstract_t">Wheatley K, Goldstone AH, Littlewood T, et al. Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. Br J Haematol 2009; 146:54.</a></li><li><a class="nounderline abstract_t">Löwenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003; 349:743.</a></li><li><a class="nounderline abstract_t">Thomas X, Raffoux E, Renneville A, et al. Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. Cancer 2010; 116:1725.</a></li><li><a class="nounderline abstract_t">Thomas X, Raffoux E, Botton Sd, et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 2007; 21:453.</a></li><li><a class="nounderline abstract_t">Pabst T, Vellenga E, van Putten W, et al. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood 2012; 119:5367.</a></li><li><a class="nounderline abstract_t">Gardner A, Mattiuzzi G, Faderl S, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol 2008; 26:5684.</a></li><li><a class="nounderline abstract_t">Ball S, Brown TJ, Das A, et al. Effect of Neutropenic Diet on Infection Rates in Cancer Patients With Neutropenia: A Meta-analysis of Randomized Controlled Trials. Am J Clin Oncol 2019; 42:270.</a></li><li><a class="nounderline abstract_t">Tramsen L, Salzmann-Manrique E, Bochennek K, et al. Lack of Effectiveness of Neutropenic Diet and Social Restrictions as Anti-Infective Measures in Children With Acute Myeloid Leukemia: An Analysis of the AML-BFM 2004 Trial. J Clin Oncol 2016; 34:2776.</a></li><li><a class="nounderline abstract_t">Segal BH, Freifeld AG, Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008; 6:122.</a></li><li><a class="nounderline abstract_t">Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.</a></li><li><a class="nounderline abstract_t">Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol 2018; 36:3043.</a></li><li><a class="nounderline abstract_t">Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 2013; 31:3360.</a></li><li><a class="nounderline abstract_t">Lim WS, Tardi PG, Dos Santos N, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res 2010; 34:1214.</a></li><li><a class="nounderline abstract_t">Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014; 15:986.</a></li><li><a class="nounderline abstract_t">Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011; 29:369.</a></li><li><a class="nounderline abstract_t">Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012; 30:3924.</a></li><li><a class="nounderline abstract_t">Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129:424.</a></li><li><a class="nounderline abstract_t">Lambert J, Pautas C, Terré C, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica 2019; 104:113.</a></li><li><a class="nounderline abstract_t">Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012; 379:1508.</a></li><li><a class="nounderline abstract_t">Fournier E, Duployez N, Ducourneau B, et al. Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. Blood 2020; 135:542.</a></li><li><a class="nounderline abstract_t">Schlenk RF, Paschka P, Krzykalla J, et al. Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. J Clin Oncol 2020; 38:623.</a></li><li><a class="nounderline abstract_t">Kapp-Schwoerer S, Weber D, Corbacioglu A, et al. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. Blood 2020; 136:3041.</a></li><li><a class="nounderline abstract_t">Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 2009; 27:5397.</a></li><li><a class="nounderline abstract_t">Arlin Z, Case DC Jr, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Leukemia 1990; 4:177.</a></li><li><a class="nounderline abstract_t">Wahlin A, Hörnsten P, Hedenus M, Malm C. Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia. Cancer Chemother Pharmacol 1991; 28:480.</a></li><li><a class="nounderline abstract_t">Pavlovsky S, Gonzalez Llaven J, Garcia Martinez MA, et al. A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia. Ann Hematol 1994; 69:11.</a></li><li><a class="nounderline abstract_t">Löwenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998; 16:872.</a></li><li><a class="nounderline abstract_t">Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004; 103:479.</a></li><li><a class="nounderline abstract_t">Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98:1302.</a></li><li><a class="nounderline abstract_t">Wang H, Mao L, Yang M, et al. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol 2022; 9:e415.</a></li><li><a class="nounderline abstract_t">DiNardo CD, Lachowiez CA, Takahashi K, et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol 2022; 97:1035.</a></li><li><a class="nounderline abstract_t">Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol 2012; 30:2441.</a></li><li><a class="nounderline abstract_t">Holowiecki J, Grosicki S, Robak T, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 2004; 18:989.</a></li><li><a class="nounderline abstract_t">Löwenberg B, Pabst T, Maertens J, et al. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood 2017; 129:1636.</a></li><li><a class="nounderline abstract_t">MacCallum PK, Davis CL, Rohatiner AZ, et al. Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence. Leukemia 1993; 7:1496.</a></li><li><a class="nounderline abstract_t">Büchner T, Hiddemann W, Wörmann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999; 93:4116.</a></li><li><a class="nounderline abstract_t">Ho AD, Lipp T, Ehninger G, et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen. J Clin Oncol 1988; 6:213.</a></li><li><a class="nounderline abstract_t">Feldman EJ, Alberts DS, Arlin Z, et al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993; 11:2002.</a></li><li><a class="nounderline abstract_t">Estey EH, Thall PF, Cortes JE, et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001; 98:3575.</a></li><li><a class="nounderline abstract_t">Russo D, Malagola M, de Vivo A, et al. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. Br J Haematol 2005; 131:172.</a></li><li><a class="nounderline abstract_t">Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood 1990; 75:27.</a></li><li><a class="nounderline abstract_t">Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 1997; 89:2311.</a></li><li><a class="nounderline abstract_t">Büchner T, Schlenk RF, Schaich M, et al. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. J Clin Oncol 2012; 30:3604.</a></li><li><a class="nounderline abstract_t">Jin J, Wang JX, Chen FF, et al. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2013; 14:599.</a></li><li><a class="nounderline abstract_t">Saini L, Brandwein J, Turner R, et al. The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease. Eur J Haematol 2016; 97:471.</a></li><li><a class="nounderline abstract_t">Seiter K, Ahmed N, Shaikh A, et al. CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients. Leuk Res 2016; 46:74.</a></li><li><a class="nounderline abstract_t">Robak T, Wrzesień-Kuś A, Lech-Marańda E, et al. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 2000; 39:121.</a></li><li><a class="nounderline abstract_t">Burnett AK, Russell NH, Hunter AE, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 2013; 122:1384.</a></li><li><a class="nounderline abstract_t">Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112:1638.</a></li><li><a class="nounderline abstract_t">Martínez-Cuadrón D, Montesinos P, Oriol A, et al. Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia. Ann Hematol 2014; 93:43.</a></li><li><a class="nounderline abstract_t">Marcault C, Venton G, Gastaud L, et al. Alternative Effective and Safe Induction Regimens for Newly Diagnosed Acute Myeloid Leukemia in Patients With Cardiac Contraindication to Anthracyclines. Clin Lymphoma Myeloma Leuk 2020; 20:e76.</a></li><li><a class="nounderline abstract_t">Vulaj V, Perissinotti AJ, Uebel JR, et al. The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia. Leuk Res 2018; 70:91.</a></li><li><a class="nounderline abstract_t">Bashey A, Liu L, Ihasz A, et al. Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older. Leuk Res 2006; 30:503.</a></li><li><a class="nounderline abstract_t">Borthakur G, Cortes JE, Estey EE, et al. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol 2014; 89:964.</a></li><li><a class="nounderline abstract_t">Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol 2021; 8:e481.</a></li><li><a class="nounderline abstract_t">Othman J, Wilhelm-Benartzi C, Dillon R, et al. A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial. Blood Adv 2023; 7:4539.</a></li><li><a class="nounderline abstract_t">Germann N, Goffinet F, Goldwasser F. Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients. Ann Oncol 2004; 15:146.</a></li><li><a class="nounderline abstract_t">Ali S, Jones GL, Culligan DJ, et al. Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy. Br J Haematol 2015; 170:487.</a></li><li><a class="nounderline abstract_t">Chelghoum Y, Vey N, Raffoux E, et al. Acute leukemia during pregnancy: a report on 37 patients and a review of the literature. Cancer 2005; 104:110.</a></li><li><a class="nounderline abstract_t">Pizzuto J, Aviles A, Noriega L, et al. Treatment of acute leukemia during pregnancy: presentation of nine cases. Cancer Treat Rep 1980; 64:679.</a></li><li><a class="nounderline abstract_t">Reynoso EE, Shepherd FA, Messner HA, et al. Acute leukemia during pregnancy: the Toronto Leukemia Study Group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents. J Clin Oncol 1987; 5:1098.</a></li><li><a class="nounderline abstract_t">Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004; 5:283.</a></li><li><a class="nounderline abstract_t">Milojkovic D, Apperley JF. How I treat leukemia during pregnancy. Blood 2014; 123:974.</a></li><li class="breakAll">Idarubicin hydrochloride injection. United States prescribing information. Revised February 2021. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050734s027lbl.pdf (Accessed on February 18, 2021).</li><li><a class="nounderline abstract_t">Bakst RL, Tallman MS, Douer D, Yahalom J. How I treat extramedullary acute myeloid leukemia. Blood 2011; 118:3785.</a></li><li><a class="nounderline abstract_t">von Keudell G, Larson RA. Positron Emission Tomography-Computed Tomography Imaging of a Patient With Several Myeloid Sarcomas With FLT3-ITD and NPM1 Mutations. J Clin Oncol 2016; 34:e123.</a></li><li><a class="nounderline abstract_t">Bakst R, Wolden S, Yahalom J. Radiation therapy for chloroma (granulocytic sarcoma). Int J Radiat Oncol Biol Phys 2012; 82:1816.</a></li><li><a class="nounderline abstract_t">Fritz J, Vogel W, Bares R, Horger M. Radiologic spectrum of extramedullary relapse of myelogenous leukemia in adults. AJR Am J Roentgenol 2007; 189:209.</a></li><li><a class="nounderline abstract_t">Lee EY, Anthony MP, Leung AY, et al. Utility of FDG PET/CT in the assessment of myeloid sarcoma. AJR Am J Roentgenol 2012; 198:1175.</a></li><li><a class="nounderline abstract_t">Lan TY, Lin DT, Tien HF, et al. Prognostic factors of treatment outcomes in patients with granulocytic sarcoma. Acta Haematol 2009; 122:238.</a></li><li><a class="nounderline abstract_t">Tsimberidou AM, Kantarjian HM, Estey E, et al. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia 2003; 17:1100.</a></li><li><a class="nounderline abstract_t">Yamauchi K, Yasuda M. Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature. Cancer 2002; 94:1739.</a></li></ol></div><div id="topicVersionRevision">Topic 4525 Version 69.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23365464" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15994282" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35767897" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732831" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35797463" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23398482" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19776406" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Anthracycline dose intensification in acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21828126" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25833957" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27268085" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20048183" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1824249" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24297940" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16721819" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23287624" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23287624" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28644114" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28644114" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37116523" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35486475" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32786187" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29545346" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29218851" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35406512" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26789727" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Assessment of Minimal Residual Disease in Standard-Risk AML.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29601269" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Molecular Minimal Residual Disease in Acute Myeloid Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33792630" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24062400" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29601212" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31395600" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33058194" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34771594" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34724563" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35179244" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33929500" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20164484" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Dose of prophylactic platelet transfusions and prevention of hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29182495" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438472" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12930926" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20143449" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17252021" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22422824" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18955453" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30628912" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effect of Neutropenic Diet on Infection Rates in Cancer Patients With Neutropenia: A Meta-analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27269945" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Lack of Effectiveness of Neutropenic Diet and Social Restrictions as Anti-Infective Measures in Children With Acute Myeloid Leukemia: An Analysis of the AML-BFM 2004 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18319048" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prevention and treatment of cancer-related infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21258094" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30179565" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23940227" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20138667" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25008258" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21172891" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22851554" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27895058" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30076173" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22482940" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31880804" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31851556" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33367545" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19826132" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2179638" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1934252" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8061102" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9508168" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14512295" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11520775" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35512726" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35583199" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22508825" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999298" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28049642" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8412309" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10361108" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3422260" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8410125" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11739159" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16197446" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2403818" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9116274" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22965967" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23664707" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27028202" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27151544" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10975390" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23838349" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18565853" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24081577" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31865004" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Alternative Effective and Safe Induction Regimens for Newly Diagnosed Acute Myeloid Leukemia in Patients With Cardiac Contraindication to Anthracyclines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29908418" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16303178" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24990142" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34171279" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37171402" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14679135" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26081614" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15912518" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Acute leukemia during pregnancy: a report on 37 patients and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6933005" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Treatment of acute leukemia during pregnancy: presentation of nine cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3474357" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Acute leukemia during pregnancy: the Toronto Leukemia Study Group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15120665" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Use of chemotherapy during human pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24269956" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : How I treat leukemia during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24269956" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : How I treat leukemia during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21795742" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : How I treat extramedullary acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24733791" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Positron Emission Tomography-Computed Tomography Imaging of a Patient With Several Myeloid Sarcomas With FLT3-ITD and NPM1 Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21962486" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Radiation therapy for chloroma (granulocytic sarcoma).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17579173" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Radiologic spectrum of extramedullary relapse of myelogenous leukemia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22528910" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Utility of FDG PET/CT in the assessment of myeloid sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19887783" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Prognostic factors of treatment outcomes in patients with granulocytic sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12764375" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920536" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
